Join Shorla Oncology at the BIO CEO and Investor Conference 2023 - Shorla Oncology: A Leader in Innovative Oncology Solutions

LATEST NEWS

Shorla Oncology co-founders win EY Entrepreneurs of the Year award

December 2nd 2024

Shorla Oncology develops and commercializes innovative oncology drugs, where existing treatments are limited, in shortage or inadequate.

November 26th 2024

Shorla Oncology Announces FDA Approval of IMKELDI (imatinib mesylate)

November 26th 2024

Shorla Oncology Announces U.S. Food and Drug Administration (FDA) Expanded Approval of JYLAMVO™ (methotrexate), an Oncology and Autoimmune Drug for Pediatric Indications

November 21st 2024

Shorla Oncology will be attending The (ACR) Convergence 2024 in Washington DC from Nov 14-19

November 13th 2024

Shorla Oncology at ASHP Mid Year 2024, New Orleans, Dec 8-12

November 11th 2024

Shorla, Protega Win Expanded Nods for Cancer/Autoimmune, Pain Therapies

November 1st 2024

FDA expands Jylamvo approval to include polyarticular juvenile idiopathic arthritis, ALL

November 1st 2024

FDA Expands Methotrexate Indication to Included Children With Acute Lymphoblastic Leukemia

November 1st 2024